TScan Therapeutics Ownership | Who Owns TScan Therapeutics?


OverviewForecastRevenueFinancialsChart

TScan Therapeutics Ownership Summary


TScan Therapeutics is owned by 24.99% institutional investors, 0.20% insiders, and 74.81% retail investors. Lynx1 capital management lp is the largest institutional shareholder, holding 6.17% of TCRX shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.50% of its assets in TScan Therapeutics shares.

TCRX Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockTScan Therapeutics24.99%0.20%74.81%
SectorHealthcare Stocks 35.58%11.87%52.55%
IndustryBiotech Stocks 35.75%11.83%52.41%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Lynx1 capital management lp8.02M6.17%$8.10M
Blackrock4.46M4.70%$26.10M
Bvf inc/il5.56M4.28%$5.62M
Ecor1 capital5.00M4.21%$15.20M
Baker bros. advisors lp2.78M2.14%$2.81M
Vanguard group2.48M1.91%$2.48M
Blackrock funding, inc. /de1.84M1.42%$1.86M
Millennium management1.46M1.12%$1.47M
Renaissance1.36M1.05%$1.38M
Deer management1.25M0.96%$1.26M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Dc funds, lp630.00K42.40%$630.00K
Lynx1 capital management lp8.02M1.28%$8.10M
Ecor1 capital5.00M0.57%$15.20M
Deer management1.25M0.20%$1.26M
Bvf inc/il5.56M0.18%$5.62M
Verdad advisers, lp134.00K0.15%$135.34K
Militia capital partners, lp102.10K0.09%$185.82K
Dc investments management35.56K0.03%$64.72K
Gsa capital partners llp378.96K0.02%$383.00K
Baker bros. advisors lp2.78M0.02%$2.81M

Top Buyers

HolderShares% AssetsChange
Blackrock4.46M0.00%2.76M
Millennium management1.46M0.00%1.06M
Jacobs levy equity management808.36K0.00%620.20K
Two sigma investments, lp1.21M0.00%557.83K
Bvf inc/il5.56M0.18%338.22K

Top Sellers

HolderShares% AssetsChange
Adage capital partners gp---3.50M
Checkpoint capital---2.02M
Propel bio management---1.93M
Alphabet---1.08M
Great point partners---1.02M

New Positions

HolderShares% AssetsChangeValue
Vanguard fiduciary trust305.77K0.00%305.77K$308.83K
Verdad advisers, lp134.00K0.15%134.00K$135.34K
Kestra advisory services62.52K0.00%62.52K$63.15K
Ameriprise financial52.63K-52.63K$53.16K
Voleon capital management lp47.88K0.00%47.88K$87.14K

Sold Out

HolderChange
Ifp advisors-7.00
Northwestern mutual wealth management-8.00
True wealth design-9.00
Eversource wealth advisors-65.00
Rothschild investment-110.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 202658-3.33%32,468,3125.78%244.47%26-3.70%195.56%
Dec 31, 202534-52.78%10,292,013-70.26%71.11%18-28.00%9-67.86%
Sep 30, 202572-4.00%34,601,2331.17%263.84%25-41.86%2864.71%
Jun 30, 202578-12.36%35,711,883-7.86%273.08%46-6.12%17-5.56%
Mar 31, 2025924.55%40,135,892-3.36%302.53%506.38%1918.75%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv1.50M2.50%-
Simplify Propel Opportunities ETF1.05M1.84%-
abrdn Life Sciences Investors836.78K1.47%-
Vanguard Institutional Extnd Mkt Idx Tr577.59K0.96%-
BlackRock Health Sciences Opps Inv A556.65K0.93%-
Invesco Dorsey Wright SmallCap Momt ETF475.53K0.90%-
BlackRock Health Sciences Term Trust407.01K0.72%-638.76K
Fidelity Small Cap Index392.73K0.69%-
Fidelity Extended Market Index319.69K0.53%48.25K
iShares Biotechnology ETF262.48K0.46%-

Recent Insider Transactions


DateNameRoleActivityValue
Dec 19, 2025Lynx1 Capital Management LP-Buy$71.97K
Dec 23, 2025Lynx1 Capital Management LP-Buy$5.60K
Dec 22, 2025Lynx1 Capital Management LP-Buy$67.95K
May 20, 2025Lynx1 Capital Management LP-Buy$1.44M
May 19, 2025Lynx1 Capital Management LP-Buy$1.67M

Insider Transactions Trends


DateBuySell
2026 Q2--
2026 Q1--
2025 Q43-
2025 Q3--
2025 Q22-

TCRX Ownership FAQ


Who Owns TScan Therapeutics?

TScan Therapeutics shareholders are primarily institutional investors at 24.99%, followed by 0.20% insiders and 74.81% retail investors. The average institutional ownership in TScan Therapeutics's industry, Biotech Stocks , is 35.75%, which TScan Therapeutics falls below.

Who owns the most shares of TScan Therapeutics?

TScan Therapeutics’s largest shareholders are Lynx1 capital management lp (8.02M shares, 6.17%), Blackrock (4.46M shares, 4.70%), and Bvf inc/il (5.56M shares, 4.28%). Together, they hold 15.16% of TScan Therapeutics’s total shares outstanding.

Does Blackrock own TScan Therapeutics?

Yes, BlackRock owns 4.70% of TScan Therapeutics, totaling 4.46M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 26.1M$. In the last quarter, BlackRock increased its holdings by 2.76M shares, a 162.61% change.

Who is TScan Therapeutics’s biggest shareholder by percentage of total assets invested?

Dc funds, lp is TScan Therapeutics’s biggest shareholder by percentage of total assets invested, with 42.40% of its assets in 630K TScan Therapeutics shares, valued at 630K$.

Who is the top mutual fund holder of TScan Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of TScan Therapeutics shares, with 2.50% of its total shares outstanding invested in 1.5M TScan Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools